Novartis Cancer-Drug Patent Denied by India Supreme Court – Bloomberg


Business Today

Novartis Cancer-Drug Patent Denied by India Supreme Court
Bloomberg
Novartis AG's (NOVN) Gleevec cancer treatment isn't eligible for a patent in India, the Supreme Court ruled, in a decision watched by non-profit groups seeking to expand access to medicines and drugmakers concerned the country is increasingly
India's top court dismisses Novartis petition for Glivec patentReuters
SC rejects Novartis's patent plea on its cancer drug, says Glivec failed innovative Hindustan Times
Lawyer: India's Supreme Court rejects Novartis AG's right to patent new version Newsday
Firstpost –NDTV
all 29 news articles »